October 3rd 2024
An expert explained the importance of education and involvement in care for patients with myeloproliferative neoplasms.
September 24th 2024
An expert discussed the findings of the COMMANDS trial evaluating Reblozyl’s role in red blood cell transfusion independence for patients with MDS.
September 20th 2024
With my myelodysplastic syndrome and age, I find it hard to keep up; however, cancer and fatigue have taught me to live at my own pace.
September 18th 2024
Although Jakafi has been approved for patients with higher-risk myelofibrosis, those with lower-risk disease may also benefit from this treatment.
An expert explained the burden that red blood cell transfusions can place on patients with MDS.
My Worries About Being Old as an MDS Survivor
Having myelodysplastic syndromes has taught me to cherish every day and to pursue the things that matter to me, like publishing a book I’ve been writing.
Essential Thrombocythemia Trial Launched Evaluating Bomedemstat
The Shorespan-007 trial will investigate the new drug among patients with essential thrombocythemia who have not previously received cytoreductive therapy.
How Bispecific Antibodies Work and What Patients Can Expect
Bispecific antibodies connect the immune system with cancer cells. They offer an efficacious treatment option, but there are side effects.
6 FDA Cancer Approvals from August 2024
In August 2024, the FDA approved six new cancer treatments, including some that haven’t previously been approved.
Cancer Survivors and Olympians Need to Be in Tune With Their Bodies
Just like athletes in the Olympics, it's important for cancer survivors to keep track of everything they feel and to know their bodies well.
NCCN Recommends Rytelo for Anemia in Patients With MDS
The National Comprehensive Cancer Network now recommends Rytelo for patients with myelodysplastic syndrome who require blood transfusions.
Iopofosine I 131 Is Promising Across Waldenstrom’s Macroglobulinemia Types
Eighty percent of patients with relapsed or refractory Waldenstrom’s macroglobulinemia responded to treatment with iopofosine I 131, researchers found.
5 Factors Linked to Greater Chance of Polycythemia Vera Progression
Researchers identified five traits that may increase a person’s chance of experiencing polycythemia vera progression.
Iclusig Leads to Better Responses Than Gleevec in Leukemia Subset
Patients with Philadelphia chromosome-positive acute lymphoblastic leukemia had better MRD statuses after receiving Iclusig, compared with Gleevec.
Survivors May Have Successful Pregnancies After Stem Cell Transplants
Contrary to past research, blood cancer survivors may have safe and successful pregnancies up to 10 years after an allogeneic stem cell transplant.
My Invisible Losses That Emerge from Cancer
Although MDS didn’t leave physical scars, the invisible ones, like side effects from treatment, are ones that linger.
Antibody Testing May Decrease Infection Risk in Blood Cancer Survivors
More frequent immunoglobulin G testing was associated with a decreased risk of severe infections in patients with CLL and non-Hodgkin lymphoma.
Some With MDS May Benefit from Delaying Stem Cell Transplants
For patients with MDS who benefit from delaying transplants, it’s important to take care of their health while savoring their time before transplant.
Don Omar Announces Being Cancer Free, ‘General Hospital’ Star Opens Up About Cancer and More
From Don Omar announcing being cancer free to “General Hospital” star John York talking about treatment for his two cancers, here’s what’s going on in the oncology space this week.
My Feeling of Survivor’s Guilt
As a cancer survivor, I realize that life doesn’t always go the way we think it will, but it doesn’t erase the guilt.
FDA-Approved Rytelo a ‘Game Changer’ for Some Patients with MDS
Approximately half of the patients with MDS who responded to treatment with Rytelo went a year without needing a blood transfusion, one expert explained.
FDA Approves Rytelo for Some With Low- to Intermediate-1-risk MDS
The Food and Drug Administration has approved Rytelo to treat certain patients with low- to intermediate-1 risk MDS with transfusion-dependent anemia.
Reblozyl Continues to Improve MDS Transfusion Independence
Patients with myelodysplastic syndromes tended to have longer periods of time without needing a red blood cell transfusion when treated with Reblozyl.
Safety Profile of Lower-Dose Oral Onureg Remains Consistent in Lower-Risk MDS
The safety profile of 200 milligrams and 300 milligrams of oral Ongureg were similar in patients with lower- to intermediate-risk MDS.
Cancer and Fatigue Go Together
As a cancer survivor, I’m pleading for more research on cancer related fatigue.
Certain Immunotherapy Drugs Not Recommended for Pregnant Women With Cancer
When possible, immune checkpoint inhibitors should be avoided in pregnant women with cancer due to lung inflammation and possible miscarriage, researchers found.
Pelabresib Combo Leads to Outcomes Linked to Better Survival in Myelofibrosis
Pelabresib plus Jakafi led to a reduction in spleen size and was tolerable in patients with myelofibrosis, according to data from MANIFEST-2.
How COVID-19 Helped Me Cope Day to Day With Cancer
I was surprised that COVID-19 taught me how to cope with the daily annoyances of cancer.
Lower Childbirth Rates Shown in Women With MPNs
Childbirth rates have been reduced by 22% in women with MPNs, compared with women without MPNs, researchers found.
FDA Approvals in the Blood Cancer Space from Early 2024
The Food and Drug Administration approved multiple new therapies for blood cancer over the last few months.
Elritercept Receives FDA Fast Track Designation for MDS Treatment
The novel treatment elritercept received a Fast Track designation from the FDA to treat anemia in patients with MDS.
Blood Cancer Expert Talks CAR-T Cell Therapy Risks, Benefits
An FDA committee voted that the benefits of Carvykti outweigh the risks for myeloma treatment, though concerns about secondary malignancies remain.
Blood Cancer Drug Decreases Levels of Anti-Fungal Medication
Patients taking Tibsovo to treat MDS or AML may want to discuss the appropriate medications to treat and prevent infections, an expert said.
FDA Committee in Favor of Imetelstat for Transfusion-Dependent MDS
The Oncologic Drug Advisory Committee voted that the benefits of imetelstat outweigh the risks for transfusion-dependent myelodysplastic syndrome and anemia.
Follow-Ups Help Prevent ‘Dangerous’ Outcomes in Blood Cancer Survivors
Attending follow-up appointments as blood cancer survivors can help prevent more dangerous outcomes, including secondary cancers, an expert told CURE®.